IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2569
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$137M
Anat Cohen-Dayag
Compugen Ltd. researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors. COM902, a therapeutic antibody targeting TIGIT, and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, are in clinical study in patients with advanced or metastatic non-small cell lung cancer.
Headcount
70
HQ Base
HOLON,
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CGEN COMPUGEN LTD | 47 | 51 | 41 | 46 | - | - | -103.7% | -49.5% | 71.5% | -53.4% | -51.1% | -16.7% | 0.0% | 0.0x | $137M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
COMPUGEN LTD (CGEN) receives a "Reduce" rating with a composite score of 46.5/100. It ranks #2569 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for CGEN.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 51 | 46 | +5NEUTRAL |
| MOMENTUM | 46 | 38 | +8ALPHA |
| VALUATION | 41 | 31 | +10ALPHA |
| INVESTMENT | 51 | 92 | -41DRAG |
| STABILITY | 46 | 37 | +9ALPHA |
| SHORT INT | 69 | 81 | -12DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -103.7% (sector -1.9%)
GM 72% vs sector 44%, OM -53% vs sector 3%
Capital turnover N/A, R&D intensity 91.1%
Rev growth -17%, 9yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate COMPUGEN LTD (CGEN) as a Reduce with a composite score of 46.5/100 at a current price of $1.76. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
COMPUGEN LTD holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 46.5/100 places it at rank #2569 in our full universe.
No Moat
High
Poor
Fair Value
Gross margins of 72% signal strong pricing power.
Stable competitive position in a defensive sector.
Vulnerability to macroeconomic shocks and interest rate volatility.
COMPUGEN LTD represents a reduce based on multi-factor quantitative performance.
COMPUGEN LTD receives a Reduce rating from our analysis, with a composite score of 46.5/100 and 2 out of 5 stars, ranking #2569 out of 7,333 stocks. CGEN's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
With a quality score of 51/100, CGEN shows adequate but unremarkable business quality. The company reports a return on equity of -103.7% (sector avg: -1.9%), gross margins of 71.5% (sector avg: 44.1%), net margins of -51.1% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
With a value score of 41/100, CGEN appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 2.96x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
With an investment score of 51/100, CGEN exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of -16.7% vs. a sector average of 6.7% and a return on assets of -49.5% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
CGEN is currently showing below-average momentum at 46/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at -16.7% year-over-year, while a beta of 1.74 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
With a stability score of 46/100, CGEN exhibits average financial resilience. Key stability metrics include a beta of 1.74 and a debt-to-equity ratio of 0.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
CGEN carries a short interest score of 69/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include high market sensitivity (beta: 1.74), micro-cap liquidity risk. At $137M market cap (micro-cap), COMPUGEN LTD offers reasonable institutional liquidity.
COMPUGEN LTD is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2569 of 7,333 overall (65th percentile). Key comparisons include ROE of -103.7% trailing the -1.9% sector median and operating margins of -53.4% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While CGEN currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (41) would have the largest impact on the composite score.
ROE 5356% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 62% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 2229% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081

CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its fourth quarter and full year 2025 financial results on Monday, March 2, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced the appointment of Michele Holcomb, Ph.D., as a new independent director, effective February 11, 2026.
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that management will participate in the following upcoming investor conferences:

Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.